Post by
canadapiet on Jan 19, 2021 5:54pm
Phone call Mrs. Leah
Me disappointed (again)!!!!
The call:
- she reads the MB because; i have e- mailed her the questions Wino was mentioning and she said she read them and suggested to eventually answer them line by line........
-regarding the Nasdaq listing and doing a capital increase by that time: "they didn't need the money then"......(OMG.....)
- they can not disclose who are the "buyers"
-they looked at the market now and decided they needed the money now because the markets were willing to deal with it now (we are in a biotech bubble she said, and now was the time to do the increase) OMG
- they could have raised more (OMG)
- Cannacord for the US and NBF for Canada
- they had other talks with banks but that was the deal they wanted ??????!!!!!(OMG)
- doing a deal with a BP is giving up on a big chunk of future profits
- tesamorelin is from the company and they want to hold it that way for now to shine later in the Nash market
- oncology to early for a good deal ????? (velosbio was preclinical and bought for 1,2 billion.......)
- they did it to streghten the balance sheet so they had the certainty to go forward and so wouldn't be blocked if the markets crashed
- the type of investors: before the deal, TH is owned by retail and individual investors, and they wanted a more diversed shareholder base (institutions)
- r&d and money : oncology can go quickly and they must be prepared fot the next fase, but they are not expecting intermediate results(?????), so that's for next year......
- fda accaptance: end of Q3 start for Nash (but still have a conversation with fda regarding the protocol, endpoints etc )
- strong financial position for now, but to early to speculate on any further capital increase
- why invest in the company now : no value for any molecule + good financial position + existing products selling better
- old shareholders : they are working to have a better relation, they understand the frustation, they are doing things better now the last 10 months, they will be recognised in the us and will have a better exposure over there, there is substantial change for the better,they have to execute and there is no room anymore for failure ..........OMG
We laughed at the end because mentioning "what's another year" if you are waiting allready such a long time and by the way "they are all shareholders and they also want the price to go up"........
Good luck all
Comment by
scarlet1967 on Jan 19, 2021 6:45pm
Please try to get your heads out of you a... and make some changes your strategies have failed will fail never worked never will be working.
Comment by
jfm1330 on Jan 19, 2021 7:12pm
Like it or not, it's what I said. They did that for risk management.
Comment by
scarlet1967 on Jan 19, 2021 7:28pm
Yep there is no risks of not getting paid multiple six figures and bonuses now even if their trials fail until next raise
Comment by
palinc2000 on Jan 20, 2021 9:52am
I agree with her comment that things have changed for the better since the last 10 months(since the new CEO) BUT this did not translate into more PERCEIVED value by the market
Comment by
realitycheck4u on Jan 20, 2021 10:45am
This post has been removed in accordance with Community Policy
Comment by
SPCEO1 on Jan 20, 2021 2:07pm
Qwerty - do you (or others) have any thoughts on this line from the presentation regarding the cancer drugs: "Easier to customize and potentially more sustainable than antibody drug conjugates" It stuck out to me that they are trying to position their PDC as a better alternative than a ADC and I wonder if there might be some truth to that?
Comment by
qwerty22 on Jan 20, 2021 2:36pm
Another thought "customize" might be referring to the scalability of the manufacturing. I think the comment is referring to the fact they have wholly synthetic manufacturing but it's not completely clear.